Monday, September 17, 2018
Halozyme: Roche receives approval for subcutaneous formulation of trastuzumab
Halozyme (HALO) announced that Roche (RHHBY) has received approval from Health Canada for a subcutaneous formulation of trastuzumab for the treatment of patients with HER2-positive breast cancer. This is a co-formulation with Halozyme’s proprietary recombinant human hyaluronidase enzyme.
https://thefly.com/landingPageNews.php?id=2791215
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.